NCT05007379 (CARMA) is a clinical trial in Breast Cancer, sponsored by Centre Oscar Lambret.

Who is sponsoring NCT05007379?

NCT05007379 is sponsored by Centre Oscar Lambret.

What condition does NCT05007379 study?

NCT05007379 studies Breast Cancer.

Is NCT05007379 still recruiting?

NCT05007379 is currently recruiting now. Last updated 18 March 2026.

Last reviewed 2026-03-18 · How we verify

NCT05007379: CARMA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids

Recruiting now Last updated 18 March 2026

What this trial tests

trial in Breast Cancer in 100 participants. Currently enrolling.

Timeline

2 November 2021

Primary endpoint
1 September 2023

1 December 2027

Quick facts

Lead sponsor	Centre Oscar Lambret
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	2 November 2021
Primary completion	1 September 2023
Estimated completion	1 December 2027
Sites	1 location across France

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Centre Oscar Lambret — full company profile →

Who can join

Adults 18 to 100, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring treatment options in cancer: Tumor treatment strategies.
Liu B, Zhou H, Tan L, Siu KTH, et al · · 2024 · cited 536× · PMID 39013849 · DOI 10.1038/s41392-024-01856-7
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K, Farrukh H, Chittepu VCSR, Xu H, et al · · 2022 · cited 478× · PMID 35361234 · DOI 10.1186/s13046-022-02327-z
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
Maalej KM, Merhi M, Inchakalody VP, Mestiri S, et al · · 2023 · cited 421× · PMID 36717905 · DOI 10.1186/s12943-023-01723-z
Organoids: The current status and biomedical applications.
Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274
Challenges and new technologies in adoptive cell therapy.
Zhang P, Zhang G, Wan X. · · 2023 · cited 153× · PMID 37596653 · DOI 10.1186/s13045-023-01492-8
Emerging Targeted Therapies for HER2-Positive Breast Cancer.
Mercogliano MF, Bruni S, Mauro FL, Schillaci R. · · 2023 · cited 95× · PMID 37046648 · DOI 10.3390/cancers15071987
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors.
Hadiloo K, Taremi S, Heidari M, Esmaeilzadeh A. · · 2023 · cited 81× · PMID 38017494 · DOI 10.1186/s40364-023-00537-x
Cancer organoid co-culture model system: Novel approach to guide precision medicine.
Yuan J, Li X, Yu S. · · 2022 · cited 68× · PMID 36713421 · DOI 10.3389/fimmu.2022.1061388

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Centre Oscar Lambret trials

Trials by the same sponsor.

NCT07507773 — Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the · Phase 2 · not yet recruiting
NCT06807164 — Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome · Phase 2 · recruiting
NCT06969833 — Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma · NA · recruiting
NCT06181201 — Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer · terminated
NCT05286684 — Feasibility of Exosome Analysis in Cerebrospinal Fluid During the Diagnostic Workup of Metastatic Meningitis · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05007379 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Oscar Lambret
Last refreshed: 18 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05007379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing